CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D006819: Hyaline Membrane Disease NIH

(Synonyms: Hyaline Membrane D, Hyaline Membrane Disease)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug370 Convalescent plasma Wiki 0.32

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D012127 Respiratory Distress Syndrome, Newborn NIH 0.12
D012128 Respiratory Distress Syndrome, Adult NIH 0.10

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Anti-MERS-COV Convalescent Plasma Therapy

Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.

NCT02190799 Respiratory Distress Syndrome ( Respiratory Distress Syndrome (& Respiratory Distress Syndrome (& [Hyaline Membrane Disease Respiratory Distress Syndrome (& [Hyaline Membrane Disease] Respiratory Distress Syndrome (& [Hyaline Membrane Disease]) Biological: Convalescent plasma
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Hyaline Membrane Disease

Primary Outcomes

Description: Hospital mortality will be death in the ICU during the same hospital admission

Measure: Hospital mortality

Time: Death in the Hospital (ICU or ward) before or at 6 months after enrollment

Secondary Outcomes

Description: Death in the ICU during the same hospital admission.

Measure: ICU mortality

Time: Death in the ICU at or after 90 days of enrollment

Description: Number of calendar days between admission and final discharge from ICU.

Measure: ICU Length of Stay

Time: Number of days in ICU with an average expected duration of 10 days.

Description: Number of calendar days between start and final liberation from mechanical ventilation.

Measure: Duration of Mechanical Ventilation

Time: Number of days of mechanical ventilation with an expected average duration of 8 days

Description: viral clearance from all sampled sites by day 3 after administration of CP

Measure: Viral load in tracheal aspirate

Time: Serial levels in the first 28 days of enrollment

Description: Epidermal Growth Factor (EGF), Eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interferon(IFN)-γ, IFN-a2, Interleukin (IL)-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, Interferon gamma-induced protein (IP)-10, Monocyte Chemotactic Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1a, MIP-1β, Tumor Necrosis Factor-α (TNF-a), TNF-β, Vascular Endothelial Growth Factor (VEGF)

Measure: Inflammatory markers,

Time: Serial levels in the first 28 days of enrollment

Description: anti-MERS-CoV antibody level before and after administration of CP.

Measure: Anti-MERS-CoV antibodies

Time: Serial levels in the first 28 days of enrollment

Other Outcomes

Description: X ray changes at day 0, 1, 3, 7, 14, 21 and 28

Measure: Chest X ray

Time: Serial changes in the X ray till day 28


HPO Nodes